A Multicenter Study on Amidolytic Factor X Evaluation in Oral Anticoagulant Therapy^[*]

Summary

For laboratory control of oral anticoagulation, amidolytic factor X (F X) determination may offer an alternative to standardization difficulties of prothrombin time (PT). In order to validate this amidolytic assay on a large scale, a multicenter study was undertaken in 6 French laboratories using the same chromogenic substrate (Stachrom X Stago) and different automated instruments. Intra and between laboratory reproducibility of factor X was estimated on fresh and lyophilized patients plasmas and was found to be highly satisfactory. Standardization of the method did not seem to depend on the chromogenic substrate used, as investigated in two different centers. Results of PT and factor X were compared in over 500 patients on a longterm stabilized oral anticoagulant treatment: there was a strong positive correlation between the 2 tests in each center. The therapeutic range for factor X was evaluated from therapeutic PT values reported by Duckert and Marbet for the different thromboplastin reagents: the estimated mean range was 21 to 32%.

Pooling the results of the six different centers a concordant information for prothrombin time and factor X amidolytic assay was found in 76% of patients and a fully discordant response was present in 0.6%. The results suggest that amidolytic factor X may be suitable for monitoring long-term anticoagulation. However, prospective trials are needed to evaluate its usefulness as compared to conventional methods.

Keywords

Oral anticoagulation - Chromogenic substrate - Amidolytic factor X - Prothrombin time

^*This study was conducted by the EMMA Group: Etude Multicentre des Methodes Amidolytiques. The names of the participants are mentioned in the Appendix.

• References

• 1 Owren PA. Critical study of tests for control of anticoagulant therapy. Thrombos Diathes Haemorrh 1962; 7 suppl (Suppl. 01) 294-305
• 2 Loeliger EA, van Halem-VisserL. Biological properties of the thromboplastins and plasmas included in the ICTH/ICSH collaborative study on prothrombin time standardization. Thromb Haemostas 1979; 42: 1115-1127
• 3 Duckert F, Marbet GA. Le contrôle du traitement aux anticoagulants oraux. La zone thérapeutique Med Hyg 1977; 35: 911
• 4 Beck EA. Standardisation et contrôle de qualité du “temps de thromboplastine” selon Quick. Med Hyg 1977; 35: 907-908
• 5 ICTH/ICSH. Prothrombin time standardization: report of the expert panel on oral anticoagulant control. Thromb Haemostas 1979; 42: 1073-1114
• 6 Loeliger EA, van Halem-VisserL. Results of calibration by the Dutch national reference laboratory of the thromboplastins included in the ICTH/ICSH collaborative study of prothrombin time standardization. Thromb Haemostas 1979; 42: 1128-1131
• 7 Poller L. British Comparative thromboplastin therapeutic range. Thromb Haemostas 1976; 36: 485
• 8 Kirkwood TB. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemostas 1983; 49: 238-244
• 9 Goguel A. Contrôle de qualité du temps de Quick. Renseignements fournis par les confrontations interlaboratoires “Etalonorme ” 1973 à 1975 Feuillets de Biologie 1976; 17: 31
• 10 Conard J, Gradelet A, Samama M. Dosage du facteur Stuart à l’aide d’un substrat synthétique au cours des traitements anticoagulants oraux, résultats préliminaires. Ann Biol Clin 1981; 39: 81-83
• 11 Erskine JG, Walker ID, Davidson JF. Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X. J Clin Pathol 1980; 33: 445-448
• 12 Italian CISMEL. Study Group. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thromb Res 1980; 19: 493-502
• 13 Lämmle B, Bounameaux H, Marbet GA, Eichlisberger R, Duckert F. Monitoring of oral anticoagulation by an amidolytic factor X assay. A long-term study in 42 patients Thromb Haemostas 1980; 44: 150-153
• 14 Van Wijk EM, Jeletich A, Ten Cate JW. The application of an automated amidolytic factor X assay in oral anticoagulant treatment. Act Chir Scand 1982; suppl 509: 117-120
• 15 Aurell L, Friberger P, Karlsson G, Cleason G. A new sensitive and highly specific peptide substrate for factor Xa. Thromb Res 1977; 11: 595-609
• 16 Lämmle B, Eichlisberger R, Haenni L, Bounameaux H, Marbet GA, Duckert F. Kontrolle der oralen Antikoagulation. Vergleich zwischen Quick und kolorimetrischem Faktor X. Bestimmung bei 107 Patienten Schweiz med Wschr 1979; 1115-1119
• 17 Van Dieijen-Visser M, Van Wersch J, Brombacher PJ, Rosing J, Hemker HC, Van Dieijen G. Use of chromogenic peptide substrate in the determination of cloning I actors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants. Haemostasis 1982; 12: 241-255
• 18 Aiach M, Fiessinger JN, Capron L, Nussas C, Housset E, Ledere M. Kinetic study of factor X during oral anticoagulation with acenocoumarol: potential value of the initiation of treatment. Thromb Haemostas 1982; 47: 69-71
• 19 Bokarew I, Kabaeva E, Kuznetsow V. The use of chromogenic substrate S-2337 in monitoring of long-term anti vitamin K therapy. Thromb Haemostas 1983; 50: 142 (Abstr)